D-Index & Metrics Best Publications
Research.com 2022 Best Scientist Award Badge
Immunology
Japan
2022

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 140 Citations 70,777 695 World Ranking 49 National Ranking 4
Medicine D-index 144 Citations 77,373 783 World Ranking 541 National Ranking 7
Best Scientists D-index 158 Citations 90,049 1,069 World Ranking 909 National Ranking 13

Research.com Recognitions

Awards & Achievements

2022 - Research.com Best Scientist Award

2022 - Research.com Medicine in Japan Leader Award

2022 - Research.com Immunology in Japan Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Immune system
  • Cytokine

Hideo Yagita mostly deals with Immunology, Cell biology, T cell, Cancer research and Cytotoxic T cell. His Immunology study is mostly concerned with Tumor necrosis factor alpha, Immune system, Natural killer T cell, Monoclonal antibody and Antigen. His Cell biology research includes elements of Cell, Antigen-presenting cell, Apoptosis, Dendritic cell and CD28.

His T cell research is multidisciplinary, relying on both T lymphocyte, Immune tolerance and FOXP3. The concepts of his Cancer research study are interwoven with issues in Natural killer cell, Interferon gamma, Pathology, TRAF2 and Immunotherapy. Hideo Yagita has researched Cytotoxic T cell in several fields, including Molecular biology, CD8 and Fas ligand.

His most cited work include:

  • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors (1236 citations)
  • Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes (1111 citations)
  • Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. (911 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Immunology, Cell biology, T cell, Cytotoxic T cell and Cancer research. His Immunology and Immune system, Antigen, CD8, Antibody and Tumor necrosis factor alpha investigations all form part of his Immunology research activities. Hideo Yagita combines subjects such as Receptor, Cell and CD40 with his study of Cell biology.

His T cell research is multidisciplinary, incorporating perspectives in Blockade and T lymphocyte. Within one scientific family, Hideo Yagita focuses on topics pertaining to Molecular biology under Cytotoxic T cell, and may sometimes address concerns connected to T-cell receptor and CD3. He works mostly in the field of Cancer research, limiting it down to topics relating to Apoptosis and, in certain cases, Cell culture, as a part of the same area of interest.

He most often published in these fields:

  • Immunology (54.25%)
  • Cell biology (23.25%)
  • T cell (21.01%)

What were the highlights of his more recent work (between 2014-2021)?

  • Immunology (54.25%)
  • Cancer research (21.10%)
  • Immune system (17.27%)

In recent papers he was focusing on the following fields of study:

Immunology, Cancer research, Immune system, T cell and Cytotoxic T cell are his primary areas of study. His Immunology research focuses on subjects like Blockade, which are linked to Melanoma. Hideo Yagita interconnects Cancer, Colorectal cancer, Immunotherapy and Notch signaling pathway in the investigation of issues within Cancer research.

As a part of the same scientific family, Hideo Yagita mostly works in the field of Immune system, focusing on Antibody and, on occasion, Molecular biology, Microfold cell and Antigen. His work deals with themes such as CD80, CD40 and Cell biology, which intersect with T cell. His Cell biology research integrates issues from Receptor and Bone marrow.

Between 2014 and 2021, his most popular works were:

  • VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. (426 citations)
  • Notch controls the survival of memory CD4+ T cells by regulating glucose uptake. (91 citations)
  • PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. (84 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Immune system
  • Cytokine

His scientific interests lie mostly in Immunology, Cancer research, Cytotoxic T cell, T cell and Immune system. His Immunology study combines topics from a wide range of disciplines, such as Apoptosis and Blockade. The various areas that Hideo Yagita examines in his Cancer research study include Flow cytometry, Lesion, Immunogenicity, Macrophage and Notch signaling pathway.

His Cytotoxic T cell research includes themes of CD86 and CD8. His studies deal with areas such as Interleukin 12, Antigen and Cell biology as well as T cell. His Cell biology study incorporates themes from Secretion and Gene expression profiling.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Yasutoshi Agata;Akemi Kawasaki;Hiroyuki Nishimura;Yasumasa Ishida.
International Immunology (1996)

1777 Citations

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Michael A. Curran;Welby Montalvo;Hideo Yagita;James P. Allison.
Proceedings of the National Academy of Sciences of the United States of America (2010)

1558 Citations

Expression of Programmed Death 1 Ligands by Murine T Cells and APC

Tomohide Yamazaki;Hisaya Akiba;Hideyuki Iwai;Hironori Matsuda.
Journal of Immunology (2002)

1178 Citations

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Takeo Nomi;Masayuki Sho;Takahiro Akahori;Kaoru Hamada.
Clinical Cancer Research (2007)

1132 Citations

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

Yuichiro Ohigashi;Masayuki Sho;Yukishige Yamada;Yoshikazu Tsurui.
Clinical Cancer Research (2005)

985 Citations

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

Tyler R. Simpson;Tyler R. Simpson;Tyler R. Simpson;Fubin Li;Welby Montalvo-Ortiz;Manuel A. Sepulveda.
Journal of Experimental Medicine (2013)

981 Citations

New aspects of natural-killer-cell surveillance and therapy of cancer

Mark J. Smyth;Yoshihiro Hayakawa;Kazuyoshi Takeda;Hideo Yagita.
Nature Reviews Cancer (2002)

876 Citations

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells.

Kazuyoshi Takeda;Yoshihiro Hayakawa;Mark J. Smyth;Nobuhiko Kayagaki.
Nature Medicine (2001)

845 Citations

ATP drives lamina propria T H 17 cell differentiation

Koji Atarashi;Junichi Nishimura;Tatsuichiro Shima;Yoshinori Umesaki.
Nature (2008)

843 Citations

The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice

Mohammed Javeed I. Ansari;Alan D. Salama;Alan D. Salama;Tanuja Chitnis;Tanuja Chitnis;R. Neal Smith.
Journal of Experimental Medicine (2003)

811 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Hideo Yagita

Mark J. Smyth

Mark J. Smyth

QIMR Berghofer Medical Research Institute

Publications: 320

Gordon J. Freeman

Gordon J. Freeman

Harvard University

Publications: 140

Arlene H. Sharpe

Arlene H. Sharpe

Harvard University

Publications: 136

Ko Okumura

Ko Okumura

Juntendo University

Publications: 127

Lieping Chen

Lieping Chen

Yale University

Publications: 125

Bruce R. Blazar

Bruce R. Blazar

University of Minnesota

Publications: 102

Zhigang Tian

Zhigang Tian

University of Science and Technology of China

Publications: 100

Joseph A. Trapani

Joseph A. Trapani

Peter MacCallum Cancer Centre

Publications: 97

Guido Kroemer

Guido Kroemer

Sorbonne University

Publications: 96

Michael Croft

Michael Croft

La Jolla Institute For Allergy & Immunology

Publications: 90

Vijay K. Kuchroo

Vijay K. Kuchroo

Harvard University

Publications: 88

Miyuki Azuma

Miyuki Azuma

Tokyo Medical and Dental University

Publications: 84

Jedd D. Wolchok

Jedd D. Wolchok

Memorial Sloan Kettering Cancer Center

Publications: 84

Byoung S. Kwon

Byoung S. Kwon

Tulane University

Publications: 79

Laurence Zitvogel

Laurence Zitvogel

Institut Gustave Roussy

Publications: 79

James P. Allison

James P. Allison

The University of Texas MD Anderson Cancer Center

Publications: 76

Trending Scientists

Martin Kornberger

Martin Kornberger

University of Edinburgh

Mahdi Jalili

Mahdi Jalili

RMIT University

Lew Goldberg

Lew Goldberg

United States Naval Research Laboratory

Robert N. Grass

Robert N. Grass

ETH Zurich

Ricardo M. Carvalho

Ricardo M. Carvalho

University of British Columbia

Penny A. Jeggo

Penny A. Jeggo

University of Sussex

Marcia I Endres

Marcia I Endres

University of Minnesota

Stephen J. Kron

Stephen J. Kron

University of Chicago

Andreas Bikfalvi

Andreas Bikfalvi

University of Bordeaux

Kozo Fujisaki

Kozo Fujisaki

Obihiro University of Agriculture and Veterinary Medicine

Benoit Ildefonse

Benoit Ildefonse

University of Montpellier

S. Barabash

S. Barabash

Swedish Institute of Space Physics

Pedro A. Piedra

Pedro A. Piedra

Baylor College of Medicine

Cameron D. Wright

Cameron D. Wright

Harvard University

Giovanni Sartor

Giovanni Sartor

University of Bologna

Anne Moyer

Anne Moyer

Stony Brook University

Something went wrong. Please try again later.